Johnson & Johnson (NYSE:JNJ) has earned a consensus rating of “Hold” from the twenty-three analysts that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $134.76.

Several equities research analysts recently issued reports on JNJ shares. Morgan Stanley boosted their price target on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, August 24th. UBS AG reiterated a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research note on Thursday, August 31st. BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Given Consensus Rating of “Hold” by Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/12/johnson-johnson-jnj-given-consensus-rating-of-hold-by-analysts.html.

In other news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson during the second quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares in the last quarter. IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson during the second quarter worth $124,000. Institutional investors own 65.90% of the company’s stock.

Johnson & Johnson (JNJ) opened at 136.65 on Thursday. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The stock has a 50 day moving average price of $132.32 and a 200-day moving average price of $130.07. The firm has a market capitalization of $366.77 billion, a PE ratio of 23.12 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.74 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.46%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.